Any current/future new fundraising through debt or equity?

No specific mention of new fundraising through debt or equity in the excerpts provided. Finance cost is expected to remain relatively stable in the near term and then reduce over the next couple of years, indicating no immediate new large debt funding planned. (Page 14) The company is not including new acquisitions in the next year's growth guidance, suggesting a focus on organic growth and optimization rather than raising fresh capital for acquisitions. (Page 14) Existing financing appears sufficient as IPO funds were previously parked and have now been invested. (Page 14) No explicit referen

Any current/future capex/capital investment/strategic investment?

No explicit mention of new acquisitions planned for FY '27; focus is on consolidating and optimizing existing acquisitions rather than pursuing new ones. Company aims to spend more time organically building and optimizing the business platform rather than chasing new acquisition targets. Investment in working capital is largely in place as of Q4 FY26; incremental working capital needs will not be significant unless growth exceeds the guided 23%. Depreciation increase is driven by MedTech segment, notably in IVD (In Vitro Diagnostics) equipment placed at customer sites under reagent rental mode

Future growth expectations in sales/revenue/volumes?

Entero Healthcare Solutions Limited targets consolidated revenue growth of 23% year-on-year for FY '27, excluding any new acquisitions. Organic growth is expected to contribute significantly, with pharma and MedTech segments both equally driving growth. The company anticipates gross margin expansion, driven by scale and playing a full commercial role in certain product lines. They expect calendarization impacts of around 11% in revenue growth. Outperformance versus industry growth is targeted at around 1.4x to 1.5x the Indian Pharmaceutical Market (IPM) growth rate. The focus will be

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth guidance for FY '27 is approximately 23%, combining ~11% calendarization impact and ~12% organic growth. Organic growth expected around 15% like-for-like, factoring in some business rationalization. EBITDA margin guidance for FY '27 is around 5%, up from 4.5% in Q4 FY '26, reflecting margin improvement from MedTech contributions, operating leverage, and exiting low-margin businesses. Operating cash flow expected to convert at least 50% of EBITDA, driven by margin expansion and working capital optimization. Return on Capital Employed (ROCE) projected to exceed 20% next ye

IN US

Sale is live|00:00:00left today

Entero Healthcare Solutions LtdQ1 FY26Retailing

Entero Healthcare Solutions Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,162P/E: 44.6Market Cap: ₹5.2K CrSector: Retailing

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

→Entero Healthcare Solutions Limited targets consolidated revenue growth of 23% year-on-year for FY '27, excluding any new acquisitions.
→Organic growth is expected to contribute significantly, with pharma and MedTech segments both equally driving growth.
→The company anticipates gross margin expansion, driven by scale and playing a full commercial role in certain product lines.
→They expect calendarization impacts of around 11% in revenue growth.
→Outperformance versus industry growth is targeted at around 1.4x to 1.5x the Indian Pharmaceutical Market (IPM) growth rate.
→The focus will be on profitable revenue growth, operational efficiencies, and higher-margin businesses while rationalizing low-margin segments.
→Incremental working capital needs are expected to be limited as most working capital is already built in the current balance sheet.
→The company foresees increasing contribution from third-party manufactured products (10-15% of sales) with higher margins than traditional distribution.

Margin guidance

→Revenue growth guidance for FY '27 is approximately 23%, combining ~11% calendarization impact and ~12% organic growth.
→Organic growth expected around 15% like-for-like, factoring in some business rationalization.
→EBITDA margin guidance for FY '27 is around 5%, up from 4.5% in Q4 FY '26, reflecting margin improvement from MedTech contributions, operating leverage, and exiting low-margin businesses.
→Operating cash flow expected to convert at least 50% of EBITDA, driven by margin expansion and working capital optimization.
→Return on Capital Employed (ROCE) projected to exceed 20% next year, up from 1.4% in the current quarter and 18.4% in Q4 FY '26, with potential to increase beyond 20% over the medium term.
→Earnings (PAT) growth continues strong, with full year PAT up 36% YoY and Q4 PAT up 44% YoY; tax rate predicted at 22-23% for FY '27.
→Finance costs expected to remain stable near term and reduce over longer term as debt levels are paid down.

3 more insights locked — sign up free to unlock

Fundraise plans

→No specific mention of new fundraising through debt or equity in the excerpts provided.
→Finance cost is expected to remain relatively stable in the near term and then reduce over the next couple of years, indicating no immediate new large debt funding planned. (Page 14)
→The company is not including new acquisitions in the next year's growth guidance, suggesting a focus on organic growth and optimization rather than raising fresh capital for acquisitions. (Page 14)
→Existing financing appears sufficient as IPO funds were previously parked and have now been invested. (Page 14)
→No explicit references to equity fundraising or plans to issue new shares in the discussion.

Order book

The transcript provided does not mention any details regarding the current or expected order book or pending orders for Entero Healthcare Solutions Limited. The discussion primarily focuses on financial performance, growth outlook, margins, acquisitions, working capital, and competitive advantages. There is no specific information related to order book or pending orders in the available pages of the document.

Capex plans

→No explicit mention of new acquisitions planned for FY '27; focus is on consolidating and optimizing existing acquisitions rather than pursuing new ones.
→Company aims to spend more time organically building and optimizing the business platform rather than chasing new acquisition targets.
→Investment in working capital is largely in place as of Q4 FY26; incremental working capital needs will not be significant unless growth exceeds the guided 23%.
→Depreciation increase is driven by MedTech segment, notably in IVD (In Vitro Diagnostics) equipment placed at customer sites under reagent rental models.
→Finance cost expected to remain stable in near term with a potential reduction over the next couple of years as debt levels are managed down.
→No direct mention of large-scale capital expenditure or strategic investments beyond optimizations and existing business expansion.

How does Entero Healthcare Solutions Ltd rank vs peers in Retailing?

Pro feature

1Entero Healthcare Solutions Ltd

See full Retailing sector rankings

Want more stocks like Entero Healthcare Solutions Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio